Creative Biolabs to Showcase Tumoroid-on-a-Chip Technology in Upcoming Webinar

Creative Biolabs announced an upcoming webinar on August 22, 2025, at 12:00 PM EDT, focusing on the innovative tumoroid-on-a-chip technology. This microfluidic-based 3D tumor model is designed to offer more physiologically relevant conditions for preclinical testing, addressing the limitations of traditional 2D cultures in replicating tumor complexity. The webinar, presented by Dr. Mohsen Akbari, Associate Professor at the University of Victoria and Director of the Laboratory for Innovations in Microengineering (LiME), aims to explore the potential of these platforms in revolutionizing cancer research.

The tumoroid-on-a-chip technology represents a significant leap forward in the field of oncology research, providing a more accurate in vitro environment that mimics the structural and cellular features of solid tumors. This advancement is crucial for early-stage drug development and immunotherapy screening, offering researchers a tool to assess drug responses more reliably and bridge the gap between laboratory findings and clinical applications. Key topics of the webinar include the evolution of tumor chips, strategies for incorporating cellular heterogeneity, and the application of these systems in preclinical drug testing and personalized oncology.

Dr. Akbari's expertise in microengineering and biomaterials, along with his contributions to the development of tumor-on-a-chip platforms, positions him as a leading voice in this innovative field. His work, which has been widely recognized and published, underscores the importance of integrating engineering principles with biological research to advance cancer treatment strategies.

Creative Biolabs, known for its comprehensive portfolio of 3D tumor modeling platforms, continues to support the oncology research community by providing advanced tools for drug development. Their offerings, including Ex Vivo Tissue Models and Organ-on-a-Chip Models, enable researchers to conduct studies under conditions that closely resemble the in vivo tumor microenvironment, paving the way for breakthroughs in immuno-oncology and combination therapy studies.